Alnylam Pharmaceuticals | ALNY - Bienes





Bienes Cambio Fecha
Acadia Pharmaceuticals USD 1.61B 41.04M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Moderna USD 11.49B 850M 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 110.95B 3.66B 2025-12
PTC Therapeutics USD 2.87B 29.66M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 126.81B 25.48B 2025-12
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Takeda JPY 15.45T 44.34B 2026-03
Tectonic Therapeutic USD 246.58M 14.46M 2026-03
Ultragenyx Pharmaceutical USD 1.3B 236M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03
Xencor USD 736.85M 138.65M 2026-03